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Sensitization via Healthy Skin Programs Th2
Responses in Individuals with Atopic Dermatitis
Louise Newell1,3, Marta E. Polak1,3, Jay Perera1, Charlotte Owen1, Peter Boyd1, Christopher Pickard1,
Peter H. Howarth1, Eugene Healy1, John W. Holloway1,2, Peter S. Friedmann1 and Michael R. Ardern-Jones1
Allergen-specific responses in atopic dermatitis (AD) are skewed toward a Th2 profile. However, individuals with
AD have been shown to make effective virus-specific Th1 responses, raising the possibility that the skin itself
contributes to driving the AD Th2 immunophenotype. Therefore, to explore the programming of immunological
sensitization by the skin, we examined the outcome of sensitization through non-lesional skin of individuals with
AD and healthy controls. Volunteers (controls, AD individuals with filaggrin gene (FLG) mutations (ADFM), and
AD individuals without FLG mutations (ADWT)) were sensitized by cutaneous application of 2,4-dinitrochloro-
benzene (DNCB), a small, highly lipophilic chemical sensitizer. At the doses tested, DNCB showed equal
penetration into skin of all groups. Clinical reactions to DNCB were significantly reduced in AD. Although both
controls and AD made systemic DNCB-specific Th1 responses, these were reduced in AD and associated with
significantly Th2-skewed DNCB-specific T-cell responses. Th2 skewing was seen in both ADFM and ADWT, with
no difference between these groups. After 3 months, DNCB-specific Th2 responses were persistent in individuals
with AD, and Th1 responses persisted in controls. These data provide evidence that when antigen penetration is
not limiting, AD skin has a specific propensity to Th2 programming, suggesting the existence of altered skin
immune signaling that is AD-specific and independent of FLG status.
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INTRODUCTION
The immune responses of individuals with atopic dermatitis
(AD) and atopic asthma are characterized by the generation of
allergen-specific Th2 cells. Null mutations in the gene encod-
ing filaggrin (FLG) occur in up to 50% of individuals with
moderate-to-severe AD (Palmer et al., 2006; Barnes, 2010).
This finding has redirected interest in understanding the role of
the epidermis in the initiation of AD, which mirrors recent
work suggesting the key role of defective bronchial epithelia in
programming immune responses in atopic asthma (Xiao et al.,
2011). Data demonstrating that skin barrier function is
defective in AD skin (Jakasa et al., 2006; Proksch et al.,
2006; O’Regan et al., 2010) and that impaired barrier function
parallels disease severity (Nemoto-Hasebe et al., 2009)
confirm that skin barrier function is important, but this does
not fully explain the immunophenotype of AD. The Th1/Th2
paradigm (Mosmann et al., 1986; Umetsu et al., 1988;
Romagnani, 2000) has been extensively explored in AD,
and we, and others, have shown that, although allergen-
specific Th1 cells can be detected in atopic and non-atopic
individuals, allergen-specific Th2 cells are present in AD
but not in non-atopic controls (Ardern-Jones et al., 2007).
A mouse model has recently provided evidence that
homozygous mutations in FLG are implicated in Th2
skewing (Fallon et al., 2009), and although genetic associa-
tion between AD and the genes IL-4, IL-4R, and IL-13 has also
been widely replicated, the precise reason for the bias toward
a cutaneous Th2 response in AD remains obscure. Indeed,
individuals with AD are not systemically immunocompro-
mised, make appropriate vaccine-specific Th1-memory cells
(Schneider et al., 2010), and have normal circulating
Treg/Th17 frequency (Maggi et al., 2007; Koga et al., 2008).
However, the fact that relative deficiency of Treg/Th17 cells
has been identified in AD skin suggests that the primary
immune defect in AD may be intrinsic to the epidermis
(Verhagen et al., 2006; Guttman-Yassky et al., 2008).
Several lines of evidence point to the skin as being centrally
involved in programming the atopic immune responses, but
up to now the definitive demonstration of this has been
lacking. Thus, there is compelling evidence that the epidermal
cytokine thymic stromal lymphopoietin (TSLP) can program
dendritic cells via increased expression of OX40 to induce the
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generation of inflammatory Th2 cells characterized by the
production of tumor necrosis factor-a in addition to the
classical Th2 cytokines (Liu, 2006; Oyoshi et al., 2010). It
has also been proposed that the Th2 allergen-specific
responses observed in AD are a result of the defective
barrier in the skin (O’Regan et al., 2008) or the chemical
properties of the proteins themselves (Shakib et al., 2008). To
address the question of whether primary epithelial regulation
is critical in determining the quality of the allergic immune
response, we used an experimental immunization system in
humans delivered via the epidermis, and compared responses
in AD and control subjects. Immunization or sensitization to
environmental proteins would be unethical, and results may
be biased by epidermal barrier function. Previous studies of
the histological features of cutaneous responses to the model
sensitizer 2,4-dinitrochlorobenzene (DNCB) in presensitized
individuals document spongiosis and perivascular
mononuclear infiltrate arising at 48 hours, which are the
hallmarks of an eczematous response (Hartman et al., 1976).
Therefore, using DNCB, which is not found in the
environment, we could track the first exposure of an antigen
through the skin and monitor the subsequent clinical and
cellular immune priming of antigen-naive individuals to an
allergen whose penetration was unaffected by the structural
integrity of the skin barrier.
RESULTS
Penetration of DNCB is independent of FLG status
DNCB has found wide use in studying contact sensitization, as
it is not present in the environment and can sensitize all
individuals by cutaneous application (Friedmann et al., 1983).
Covalent DNCB haptenation of host proteins is a prerequisite
for the induction of contact hypersensitivity: the DNCB-
modified proteins being processed and presented in both
class I and II major histocompatibility complex pathways to
CD8 and CD4 T lymphocytes (Pickard et al., 2007).
Consequently, tracking T-cell sensitization to DNCB gives a
unique view of the initiation of immune responses generated
by percutaneous antigen exposure in humans. DNCB is a low-
molecular-weight (202 Da) highly lipophilic molecule that
penetrates the skin efficiently independent of skin structural
barrier function (Gawkrodger et al., 1989; Falconer et al.,
1992; Tsai et al., 2001). Equivalent penetration of DNCB at
the sensitizing dose in AD and controls is critical to this study;
therefore, we first set out to confirm this assumption. Using the
established methodology developed by Franz et al. (2009),
we tested the penetration of DNCB in human explant skin.
In subsequent clinical studies, we used a sensitizing dose
that has been shown to sensitize 100% of individuals
(60mg cm2). However, to avoid missing subtle alterations
in penetration, we used only 20mg cm2 in penetration
assays, which would only sensitize approximately half the
population (Friedmann et al., 1983). Following overnight
penetration of DNCB through the surface of skin biopsies
from healthy controls, individuals with AD without FLG
mutations (ADWT), or individuals with AD with FLG
mutations (ADFM), anti-DNCB fluorescence staining of
histological sections was used to assess penetration of the
antigen (Figure 1a–f). Although we cannot extrapolate these
data to lower doses of DNCB, as expected, at one-third of the
dose used in subsequent clinical experiments, equivalent
strong penetration to the basement membrane was identified
histologically between controls, and individuals with ADWT,
and individuals with ADFM, and the relative fluorescence of
anti-DNCB at the outermost viable epidermal level (base of
stratum corneum) compared with the basal keratinocyte layer
showed no significant difference between controls, individuals
with ADWT, and individuals with ADFM (Figure 1h).
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Figure 1. 2,4-Dinitrochlorobenzene (DNCB) penetration through the epidermis. (a, b) DNCB (20mg cm2) was applied to the epidermis of skin biopsies
from controls, (c, d) from individuals with atopic dermatitis without filaggrin mutation (ADWT), or (e, f) from filaggrin mutation heterozygote (ADFM) individuals.
DNCB penetration was analyzed by immunohistochemistry with (a–f) anti-DNCB or (g) representative antibody control (green). Penetration of DNCB was assessed
by measurement of the relative fluorescence of anti-DNCB (12 independent readings) from the base of the stratum corneum vs. the basal layer, as indicated by
white dotted lines, (h) using image analysis software. Error bars represent mean±SEM. NS, no statistical significance. Scale bar¼ 10mm.
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Circulating lymphocytes in AD show a normal Th1/2 ratio
A Th2-polarized repertoire of circulating T cells in AD would
be likely to modify immune priming toward Th2, and
thus would complicate the investigation of the epithelial
regulation of immune responses. Therefore, we first character-
ized the Th1/2 balance of circulating T cells in individuals
with AD and controls in our population. First, we compared
the production of IL-4 and IFN-g by ex vivo peripheral
blood mononuclear cells (PBMCs) from individuals with AD
(n¼ 18) and healthy controls (n¼10), and confirmed that
resting unstimulated cells showed no difference in basal
production of IL-4 (P¼0.37) or IFN-g (P¼0.94) (data not
shown). We then compared non-TCR mitogen–induced T-cell
activation (phytohemagglutinin (PHA)) against a direct TCR
signal delivered by Staphylococcal enterotoxin B (SEB). SEB
crosslinks specific SEB-binding TCR-Vb chains to major
histocompatibility complex II, thereby inducing T-cell activa-
tion in a subset of responding T cells. In vitro activation
showed that there was no significant difference in Th1
responses between PBMCs from both AD and controls when
stimulated by PHA or SEB: P¼0.06 and P¼0.1, respectively
(Figure 2). Importantly, circulating T cells in both AD and
controls showed a similar frequency of Th2-polarized cells
with no statistically significant difference in frequency or ratio
between the groups (Figure 2). PBMC responses to house
dust mite showed the expected Th2 programming in AD,
which was absent in controls (Figure 2e). Therefore, it seems
likely that the Th2-polarized responses to environmental
proteins characteristic of AD are contained within a very
small fraction of circulating lymphocytes, and because of such
low frequency they are unlikely in themselves to perpetuate
Th2 programming.
AD associates with impaired allergic contact dermatitis (ACD)
responses to DNCB
One month after sensitization, participants were rechallenged
on a different non-eczematous site by epicutaneous applica-
tion of a dose series of DNCB, as we have previously
described (Pickard et al., 2009). In concordance with
previous findings (Rees et al., 1990), individuals with AD
showed significantly reduced contact hypersensitivity
responses to DNCB compared with healthy controls. This
was reflected both by reduced inflammatory edema (skinfold
thickness) (Figure 3a, P¼ 0.007) and erythema (Figure 3b,
P¼0.015). Calculation of the area under the dose–response
curve in each of healthy controls, individuals with ADFM, and
individuals with ADWT, demonstrated that, compared with
healthy controls, reduced cutaneous reactivity (skinfold thick-
ness and erythema) was evident in both individuals with
ADWT and individuals with ADFM (Figure 3c and d). ADFM
showed further reduced skinfold responses to DNCB chal-
lenge as compared with ADWT, but this difference did not
reach statistical significance (P¼0.44, Figure 3c).
DNCB-specific Th1 and Th2 responses
To demonstrate that circulating DNCB-specific T cells could
be characterized in DNCB-sensitized individuals, we first
confirmed by ELISpot and flow cytometric double cytokine
intracellular staining that both Th1 (Figure 4a and c) and Th2
(Figure 4d and f) DNCB-specific T-cell lines could be
expanded in culture from the PBMCs of sensitized individuals
to high frequencies. As expected, IFN-g-producing DNCB-
specific T cells were not able to simultaneously produce IL-4
(Figure 4c). Similarly, IL-4-specific T cells were unable to
produce IFN-g (Figure 4f).
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Figure 2. Circulating lymphocytes in atopic dermatitis (AD) show a normal Th1/2 ratio. (a, b) Sixteen-hour IFN-g ELISpot and (c, d) IL-4 ELISpot assay
of ex vivo peripheral blood mononuclear cell (PBMC) activation with either phytohemagglutinin (PHA) (a, c) or Staphylococcal enterotoxin B (SEB) (b, d) in
control individuals (gray lines) or in individuals with AD (black lines). (e) Ex vivo PBMC IL-4 ELISpot stimulated with house dust mite (HDM) extract.
AD, n¼ 18; Control, n¼ 10. *Po0.05. SFU, spot-forming units.
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Sensitization through the skin induces skewing toward
antigen-specific Th2 responses in AD
To examine the cytokine polarization of antigen-specific
T cells following cutaneous sensitization with DNCB, PBMCs
from patients and controls were tested ex vivo for DNCB-
specific IFN-g and IL-4 production by ELISpot assay (Figure 5a
and b). No IFN-g or IL-4 DNCB-specific responses were
detected in non-DNCB-sensitized controls (Figure 5a and b).
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Figure 3. Atopic dermatitis (AD) subjects have impaired allergic contact dermatitis responses to 2,4-dinitrochlorobenzene (DNCB). Clinical response to
epicutaneous challenge with DNCB 1 month following sensitization through the skin in AD (black lines) and controls (gray lines). Change in (a) skinfold thickness
and (b) erythema index. (c) Area under the curve (AUC) for change in skinfold thickness and (d) erythema index for DNCB-elicitation reactions in controls
or in individuals with AD with (ADFM) or without filaggrin mutations (ADWT). NS, no statistical significance.
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Figure 4. 2,4-Dinitrochlorobenzene (DNCB)-specific Th1 and Th2 cells. (a, d) DNCB-specific responses detected in peripheral blood mononuclear cells (PBMCs)
(ex vivo; gray bars) or after short-term culture with DNCB (line; black bars) by (a) IFN-g or (d) IL-4 ELISpot from a DNCB-sensitized atopic individual.
(b, c, e, f) Flow cytometric analysis of IFN-g or IL-4 production by (c, f) activated DNCB-expanded T-cell lines or (b, e) unstimulated control PBMCs. (a, c) Low-
frequency Th1 and (d, f) Th2 cells can be detected ex vivo, but higher frequency responses are detected after short-term culture expansion. Population
frequency (%) as indicated in appropriate quartiles. Representative examples are shown. SFU, spot-forming units.
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Although both groups demonstrated Th1 DNCB-specific
responses (Figure 5b), induction of DNCB-specific Th2
responses were largely confined to AD individuals (P¼0.02)
(Figure 5a). Antigen-specific Th2 responses were significantly
more frequent in both ADWT and ADFM (P¼0.02 and 0.001,
respectively, Figure 5c). ADFM showed a greater frequency of
Th2-polarized DNCB-specific T cells compared with ADWT;
however, this did not reach statistical significance (P¼0.59;
Figure 5c).
Long-lived DNCB-specific Th2 memory cells in AD
Examination of the cohort 3 months after the rechallenge
(4 months post sensitization) showed that DNCB-specific Th2
memory responses persist in individuals with AD (Figure 5d).
However, memory-Th1 responses are diminished in the AD
group at this stage, which is in contrast to healthy controls
who maintain Th1-memory responses to DNCB (Figure 5e),
although these differences were not statistically significant.
DISCUSSION
The important role of FLG-mediated epithelial barrier dysfunc-
tion in mediating AD is assumed, but the same genetic defect
is also present in some healthy individuals without AD (9%
European population (Palmer et al., 2006)) and Ichthyosis
Vulgaris patients without AD (Smith et al., 2006). Indeed, it
has been established that epidermal barrier function is
defective in both eczematous and clinically normal skin of
individuals with AD, and application of allergens (e.g., house
dust mite proteins) to the skin can induce skin lesions (Darsow
and Ring, 2000; Ring et al., 2001) that are indistinguishable
clinically and microscopically from AD (Langeveld-Wildschut
et al., 1995, 1996), thus supporting an important role for
allergic sensitization in AD pathogenesis. Furthermore,
allergen avoidance has been shown by some to be at least
partially effective in the treatment of AD (Clark and Adinoff,
1989; Fukuda et al., 1991; Sanda et al., 1992; Tan et al., 1996;
Friedmann, 1999). Dysregulation of adaptive immunity in AD
is reflected by Th2-biased allergen-specific responses, which
are critical to B-cell class switching and induction of allergen-
specific IgE production. We have confirmed that circulating
Der p 1–specific Th2 cells are only present in atopic
individuals including those with AD, whereas Der p 1–
specific Th1 cells are detectable in both atopic subjects and
healthy controls (Ardern-Jones et al., 2007). This suggests that
although allergen has been encountered by both groups in a
setting that initiates the expansion of allergen-specific T cells,
the immune response is differently skewed in individuals with
atopy and AD. In the atopic march described in children, AD
usually arises first, most frequently in the absence of IgE
sensitization (Kay et al., 1994; Illi et al., 2004), and is a major
risk factor for the development of severe asthma and food
allergy (Sporik et al., 1990; Illi et al., 2006). The development
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of specific IgE to environmental allergens is associated with
defective skin barrier function (Boralevi et al., 2008), with skin-
related sensitization contributing to the association between
AD and childhood asthma, as well as its persistence into
adulthood (Burgess et al., 2008). Understanding the molecular
pathway that drives Th2 polarization and in turn induces
allergen-specific IgE production in individuals with AD is
critical to the further development of therapeutic approaches
for AD and potentially for atopic disease in general. Some
previous studies have shown deficient Th1 pathways in
circulating antigen-presenting cells/monocytes (IL-12) in AD,
but others have shown opposing results (Itazawa et al., 2003;
Piancatelli et al., 2008).
We therefore set out to explore the immunological outcome
of the same antigenic stimulus in the skin of individuals with
AD versus non-atopic controls. As a chemical sensitizer, DNCB
has a number of disadvantages as a model allergen for AD,
because it may not replicate the cutaneous response to protein
allergens. However, DNCB reliably sensitizes all individuals,
and, importantly, in contrast to proteins, skin penetration at the
sensitizing dose used here is not modified by AD or FLG status
(Figure 1), allowing us to test epidermal regulation of immune
responses between AD and controls without being confounded
by disease status. Furthermore, DNCB-haptenated proteins
require intracellular processing for presentation at the major
histocompatibility complex in the immunological synapse, and
therefore DNCB sensitization reflects the classical model of
T-cell antigen recognition (Pickard et al., 2007). Here, we
showed that clinical responses to DNCB were significantly
attenuated in AD (Figure 3), suggesting that individuals with
AD show a significantly impaired immune response to this
antigen. Furthermore, ADFM and ADWT showed similar
impairments in cutaneous immunity to DNCB, suggesting that
the immune dysregulation is not FLG dependent but is due to
other AD-specific epidermal factors and may be protective
against more inflammatory Th1 responses classically associated
with ACD. These findings are in line with clinical observations
reporting a lack of association between FLG mutations with a
phenotype of patients with both AD and ACD (Carlsen et al.,
2011). Nickel ACD has been reported to associate with the
presence of FLG mutations (Thyssen et al., 2008), but others
have only found a nonsignificant trend toward this finding
(Carlsen et al., 2010). The lack of histidine-rich FLG proteins
leading to increased penetration of the metal could explain a
nickel-specific association with loss of FLG protein in FLG
mutations, but there is no evidence that other contact allergens
bind FLG (Carlsen et al., 2010). In addition, FLG mutations
impair impermeability of the epidermal water barrier, and
because nickel is water soluble it is probable that percutaneous
absorption of nickel will be greater in individuals with FLG
mutations.
It has previously been shown that higher doses of DNCB
correlate with increased sensitizing potential, and therefore it
would be expected that skin penetration is highly efficient in
all individuals at a dose that sensitizes 100% of the popula-
tion, as used here (Friedmann et al., 1983). To enhance the
detection of differences in the penetration studies, we showed
that a dose of DNCB that would be expected to sensitize
approximately half the population efficiently penetrated to the
basement membrane in individuals with AD and controls.
Although these data do not exclude the possibility of
differences in DNCB penetration at lower concentrations,
we feel that the equal DNCB penetration at the tested dose
allowed us to directly compare the immune responses to
DNCB in AD patients and healthy individuals.
Therefore, in this study, we could be sure that priming of the
immune response was initiated by equal cutaneous exposure
to antigen in both AD and controls. DNCB would then be
carried and presented by cutaneous dendritic cells for T-cell
priming in the draining lymph node. In this way, we hoped to
determine the effect of the skin on induction of subsequent
immune responses in AD and controls without significant
effects manifested by differences in other immunological
compartments. Although variation in lymph node function
could contribute to the observed differences, it has been
previously shown that vaccination in the arm (bypassing the
skin, utilizing axillary lymph node drainage as in this study) is
equally effective at inducing Th1 responses in AD and controls
(Leung et al., 1988; Schneider et al., 2010). Furthermore, we
showed that in AD the circulating lymphocyte compartment
was not uniquely skewed toward Th2 (Figure 2), as compared
with controls, and previous reports have shown that serum
levels of IL-4 in AD are normal (Takahashi et al., 1992).
Despite the evident reduced skin responsiveness to DNCB in
AD, both ADWT and ADFM showed significantly greater
DNCB-specific Th2 responses than controls (Figure 5). Taken
together, it seems likely that skewing of DNCB responses
toward Th2 in AD is due to skin-specific regulation of DC
signals determining polarization of immune responses to
antigens encountered in the skin. We speculate that the
altered function of cutaneous dendritic cells may explain the
induction of DNCB-specific Th2 cells in AD, which would
result in a less inflammatory response on antigen challenge,
accounting for the impaired clinical responses seen here. We
have also found that in biopsies from positive-DNCB skin
challenge sites, gene transcription of IL-10 is higher in
individuals with AD than in controls (data not shown), which
may suggest that coregulation of regulatory cytokines in the
skin is important in manifesting a reduced inflammatory
reaction. Interestingly, controls were better able to maintain
their Th1-memory population than AD patients (Figure 5),
which we further speculate may suggest that altered program-
ming by keratinocyte-derived TSLP in AD skin results in
preferential maintenance of memory Th2 populations at the
expense of Th1 skin–sensitized memory cells (Wang et al.,
2006).
These data would be predicted to be relevant for ACD.
Recent evidence shows that ACD in AD is identified at least as
frequently as in controls (Gittler et al., 2012). Our data
demonstrate that once sensitized, individuals with AD are
likely to elicit weaker responses on cutaneous re-exposure.
This may suggest that the sensitivity of patch testing may be
lower in AD, and thus allergic sensitization may be higher
than that characterized by standard testing.
The altered innate immune responses of the epithelia and
particularly the epidermis suggest mechanisms by which
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adaptive immune responses activated via the trans-epidermal
route can be programmed or directed toward Th2 responses.
Although there is deficient production of key components of
antimicrobial innate defenses, IFN-a in the bronchial epithe-
lium and beta defensins and cathelicidins in the epidermis,
there is augmented production of prostaglandin E2 (Bao et al.,
2011; Kalinski, 2012), GMCSF (Willart et al., 2012), and TSLP
(Soumelis et al., 2002). These are all able to condition T cells
toward the Th2 phenotype by modifying their activation by
dendritic cells. Most particularly, TSLP can program dendritic
cells via increased expression of OX40 to induce the
generation of inflammatory Th2 cells characterized by the
production of tumor necrosis factor-a in addition to the
classical Th2 cytokines (Liu, 2006; Oyoshi et al., 2010). We
wished to test the hypothesis that the epidermis of individuals
with AD does indeed program a Th2 response to antigens
encountered via the trans-epidermal route. We took the
approach of inducing a new immune response with a
widely used experimental organic contact sensitizer, DNCB,
not found in the environment. A major advantage of DNCB is
that as it is not water soluble its absorption into human
epidermis would not be affected by the defective water-
permeability barrier found in many atopic patients—which
we confirm. The normal human response to this and most
small molecular contact sensitizers is known to be mediated
by Th1 and Tc1 T cells (Pickard et al., 2007). We have been
able to show that, in complete contrast to the normal, non-
atopic response, when individuals with AD are sensitized
through normal skin with DNCB, they indeed generate a
substantial Th2 response to this agent. This demonstrates that
the skin in humans with AD contributes to programming the
adaptive T-cell response toward the Th2 type, which to our
knowledge is previously unreported. This finding should direct
future research to focus on the role of epithelia of skin and
airways in programming the adaptive immune responses that
characterize the atopic state.
The data presented here demonstrate that AD skin is
immunologically dysfunctional and that this manifests as
impaired cutaneous reactivity to chemical antigens and is
associated with Th2 polarization of the adaptive immune
response. TSLP, a master regulator of Th2 polarization, has
been shown to be upregulated in lesional, but not in non-
lesional, AD skin (Soumelis et al., 2002); therefore, as these
data were from non-lesional AD, they suggest a different
AD-specific Th2 pathway. AD skin–specific Th2 skewing is of
relevance to the disease pathogenesis, and characterization of
key epidermal signals in AD skin critical to Th2 polarization
will offer therapeutic targets for the T-cell–mediated allergic
component of the disease and potentially for preventing future
atopic disease in these individuals.
MATERIALS AND METHODS
Subjects
Informed, written consent was obtained as per approval by the local
research ethics committee (NRES07/Q1704/46) in adherence with the
Helsinki guidelines. Adult AD patients with mild to severe disease
(mean objective SCORAD 33.5±11.7, Supplementary Table S1
online) were recruited through the Dermatology Centre, Southampton
University Hospital NHS Trust, for comparison with a cohort of
healthy non-atopic controls. All AD patients fulfilled the diagnostic
criteria for AD as defined by the UK. AD diagnostic criteria (Williams
et al., 1994a; Williams et al., 1994b; Williams et al., 1994c).
Objective SCORAD was measured as described previously (Schmitt
et al., 2007).
Quantification of contact sensitization by DNCB
Individuals with AD and controls were sensitized to DNCB (Sigma,
Poole, UK) at a concentration of 60mg cm 2 in acetone by epicuta-
neous patch application to the upper inner arm skin at a non-lesional
site (free from eczema) according to our previous method (Pickard
et al., 2007, 2009). In all AD volunteers, this site showed no evidence
of active eczema, and the volunteers were not being treated with
topical therapy. Four weeks later, the strength of sensitization was
determined by measurement of responses to simultaneous patch
challenge with doses of 6.25, 8.8, 12.5, and 17.7mg of DNCB to
the opposite upper inner arm (free from eczema). Clinical responses
were quantified 48 hours later at each challenge site by measuring the
change in skinfold thickness with Harpenden skinfold calipers and
erythema index (Dia-Stron, Andover, UK) as described previously
(Patil et al., 1998; Paramasivan et al., 2009). Responses at challenged
sites were expressed as a net increase after subtraction of baseline
readings taken from adjacent normal skin. Values at each challenge
site were summed to give a single value approximating to the area
under the curve.
T-cell culture
PBMCs were separated from whole blood by centrifugation on
Lymphoprep (Axis-Shield PoC, Oslo, Norway); they were then
washed and resuspended in R10HS: RPMI medium (Invitrogen,
Carlsbad, CA) supplemented with penicillin per 100 IU ml 1, strep-
tomycin 100mg ml 1, and heat-inactivated pooled human serum
(Sigma). DNCB was added at a final concentration of 2mM. The cells
were incubated at 37 1C with 5% CO2, with IL-2 (100 IU ml
 1) and
IL-7 (1mg ml 1) supplemented at day 7. At day 13, these cells were
harvested, washed, and returned overnight to wells containing
R10HS.
ELISpot assays
Ex vivo PBMCs were tested at a density of 2.5 105 cells per well; for
T-cell lines, input cell numbers were 5 104 per well. DNCB was
added at a final concentration of 2mM. For PHA and SEB experiments,
the final concentrations are shown in the figure (Figure 2). The plates
were incubated overnight at 37 1C in 5% CO2 and were developed
with streptavidin–alkaline phosphatase (Mabtech AB, Cincinnati, OH)
and the alkaline phosphatase conjugate substrate kit (Bio-Rad,
Hercules, CA). All experiments included vehicle as a negative control,
and phytohemagglutinin (PHA) was used as a positive control. DNCB-
specific responses were calculated by subtracting the counts from
control wells, and the results were expressed as spot-forming units per
million cells plated. Positive responses were recorded as those
responses greater than the mean of all the background samples plus
three times the SD of the background population.
Intracellular cytokine staining
Culture-expanded DNCB-specific lymphocytes were activated
with SEB (0.1mg ml 1) and anti-CD28 (1mg ml 1), with GolgiPlug
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(BD Biosciences, Oxford, UK). The Cytofix/Cytoperm kit (BD Bio-
sciences) was used according to the manufacturers’ instructions.
Flow cytometric analysis with the FACS Aria flow cytometer
(BD Biosciences) was undertaken following lymphocyte gating on
Forward/Side scatter and exclusion of dead cells (AQUA, Invitrogen,
Paisley, UK). Subsequent gating on CD3-FITC and CD4-PerCP
(BD Biosciences) was based on appropriate negative controls to
demonstrate IFN-g- and IL-4-positive cells (Invitrogen and BD
Biosciences) for analysis with the FlowJo software (Tree Star,
Ashland, OR).
DNCB skin penetration and staining of frozen sections
Skin explants from mastectomy tissue (healthy controls), AD FLG
wild-type, and AD FLG variant subjects were mounted in modified
Franz diffusion chambers. Skin penetration studies were undertaken
as described previously (Gawkrodger et al., 1989; Franz et al., 2009).
Briefly, DNCB (20mg cm 2) in vehicle (acetone) was applied to the
epidermal surface at 33% of the clinically used sensitizing dose to
increase the possibility of identifying small differences in penetration.
Explants were incubated overnight at 37 1C in 5% CO2 and then
snap-frozen in liquid nitrogen. Frozen skin sections were cut using a
cryostat and stained with a polyclonal goat anti-dinitrophenyl anti-
body (Sigma-Aldrich, Gillingham, UK; 1:2,000) for 1 hour at room
temperature; next, an FITC-labeled anti-goat secondary antibody
was added (Sigma-Aldrich; 1:400). Staining was visualized with
fluorescent or confocal microscopy, and images were analyzed
with ImageJ (Abramoff et al., 2004). The investigator undertaking
image analysis was blinded to the subject disease or FLG status.
FLG genotyping
FLG mutation analysis was performed as described previously
(see Supplementary Material online for further information;
Sandilands et al., 2007; Enomoto et al., 2008).
Statistical analysis
See Supplementary Material online.
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